Charles River Laboratories International, Inc.
Every calculator, already run for CRL
Open the full toolkit →You have the numbers on CRL. Get the argument.
A written report on which of these readings actually decide the outcome for Charles River Laboratories International, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
16 analysts covering CRLAnalyst Price Target Disagreement for Charles River Laboratories International, Inc.
Wall Street's bull case implies +15% from the current price; the bear case implies -48%. A 63% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CRL
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Asse…
CRL — frequently asked
Is CRL a buy right now?
Wall Street's consensus rating on Charles River Laboratories International, Inc. is Buy across 16 analysts, with a mean price target of $282.43 (+2% vs. the current $278.06). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is CRL overvalued?
CRL trades at — trailing earnings, against a DCF fair value of $173 per share. The current price implies 12% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is CRL's next earnings date?
Charles River Laboratories International, Inc. is next scheduled to report earnings around Nov 4, 2026. A full CRL research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Charles River Laboratories International, Inc.?
Analysts covering Charles River Laboratories International, Inc. (CRL) range from a bear-case target of $145.00 to a bull-case high of $320.00, with a mean consensus target of $282.43 across 14 analysts. The spread of $175.00 (63% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Charles River Laboratories International, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Charles River Laboratories International, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CRL research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Charles River Laboratories International, Inc., in minutes. 3 free reports included with every account — no credit card required.